HRP20151357T1 - Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa - Google Patents
Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa Download PDFInfo
- Publication number
- HRP20151357T1 HRP20151357T1 HRP20151357TT HRP20151357T HRP20151357T1 HR P20151357 T1 HRP20151357 T1 HR P20151357T1 HR P20151357T T HRP20151357T T HR P20151357TT HR P20151357 T HRP20151357 T HR P20151357T HR P20151357 T1 HRP20151357 T1 HR P20151357T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition according
- formula
- particles
- pharmaceutical composition
- compound
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims 13
- 239000007787 solid Substances 0.000 title claims 8
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 239000000377 silicon dioxide Substances 0.000 claims 6
- 239000011148 porous material Substances 0.000 claims 4
- 235000012239 silicon dioxide Nutrition 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 2
- 229910002011 hydrophilic fumed silica Inorganic materials 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 claims 1
- 229960003586 elvitegravir Drugs 0.000 claims 1
- 229960000366 emtricitabine Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (22)
1. Kompozicija se sastoji od mnoštva čestica čvrstog nosača gdje svaka od njih sadrži silicij dioksid i gdje svaka ima površinu i/ili pore; i spoj formule (I):
[image]
ili njegovu farmaceutski prihvatljivu sol u porama ili na površini čestica čvrstog nosača.
2. Kompozicija prema patentnom zahtjevu 1 gdje čestice silicij dioksida imaju srednju vrijednost presjeka čestica od 10 do 120 mikrona i BET površinu od 40 do 400 m2/g.
3. Kompozicija prema patentnom zahtjevu 2 gdje su čestice silicij dioksida hidrofilna pirogena silika .
4. Kompozicija prema bilo kojem od patentnih zahtjeva od 1 do 3 gdje postotak težine spoja u formuli (I) iznosi do 50% ± 10% čestica čvrstog nosača.
5. Kompozicija prema bilo kojem od patentnih zahtjeva od 1 do 4 gdje spoj formule (I) ima obogaćenu koncentraciju od 99 ± 1% stereoizomera formule (Ia):
[image]
6. Metoda sadrži kombinirani spoj formule (I):
[image]
odgovarajućeg rastvarača, i mnoštva čestica čvrstog nosača od kojih svaka sadrži silicij dioksid kako bi se dobila mješavina.
7. Tableta sadrži: 1) spoj formule (I):
[image]
ili njegovu farmaceutski prihvatljivu sol i 2) mnoštvo čestica čvrstog nosača od kojih svaka sadrži silicij dioksid.
8. Tableta prema patentnom zahtjevu 7 gdje mnoštvo čestica čvrstog nosača sadrži mnoštvo silika čestica od kojih svaka ima površinu i pore, i koje imaju srednju vrijednost presjeka čestica 10 do 120 μm i BET površinu od 40 do 400 m2/g.
9. Tableta prema patentnim zahtjevima 7 ili 8 koja dalje sadrži drugi terapeutski agens.
10. Tableta prema patentnom zahtjevu 7 koja dalje sadrži 3) mikrokristalnu celulozu; 4) hidroksipropil celulozu; 5) natrij kroskarmelozu; i 6) magnezij stearat.
11. Tableta prema bilo kojem od patentnih zahtjeva od 7 do 10 gdje spoj formule (I) ima obogaćenu koncentraciju od 99 ± 1% stereoizomera formule (Ia):
[image]
12. Farmaceutska kompozicija sadrži kvaternarnu kombinaciju spoja formule (Ia)/tenofovir disoproksil fumarat/emtricitabin/elvitegravir, i mnoštvo čestica čvrstog nosača od kojih svaka sadrži silicij dioksid, gdje je spoj formule (Ia):
[image]
13. Farmaceutska kompozicija prema patentnom zahtjevu 12 gdje čestice silicij dioksida imaju srednju vrijednost presjeka čestica od 10 do 120 μm i BET površinu od 40 to 400 m2/g.
14. Farmaceutska kompozicija prema patentnom zahtjevu 13 gdje su čestice silicij dioksida hidrofilna pirogena silika.
15. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva od 12 do 14 gdje čestice silicij dioksida imaju srednju vrijednost presjeka zrna od 20 do 40 μm.
16. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva od 12 do 15 gdje čestice silicij dioksida imaju BET površinu od najmanje 150 m2/g.
17. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva od 12 do 16 gdje je spoj formule (Ia) obloženo u porama i na površini čestica silicij dioksida.
18. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva od 12 do 17 gdje odnos težine spoja formule (Ia) do težine čestica silicij dioksida iznosi 1 ± 0.05%.
19. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva od 13 do 18 koja je formulirana kao tableta.
20. Kompozicija prema bilo kojem od patentnih zahtjeva od 1 do 5, tableta prema bilo kojem od patentnih zahtjeva od 7 do 11, ili farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva od 12 do 19 za upotrebu pri medicinskoj terapiji.
21. Kompozicija prema bilo kojem od patentnih zahtjeva od 1 do 5, tableta prema bilo kojem od patentnih zahtjeva od 7 do 11, ili farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva od 12 do 19 za upotrebu u liječenju virusnih infekcija.
22. Kompozicija za upotrebu kako je naznačeno u patentnom zahtjevu 21, ili tableta za upotrebu kako je naznačeno u patentnom zahtjevu 21, ili farmaceutska kompozicija za upotrebu kako je naznačeno u patentnom zahtjevu 21, gdje je virusna infekcija HIV.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4993508P | 2008-05-02 | 2008-05-02 | |
| US15065209P | 2009-02-06 | 2009-02-06 | |
| US15065509P | 2009-02-06 | 2009-02-06 | |
| PCT/US2009/042607 WO2009135179A2 (en) | 2008-05-02 | 2009-05-01 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| EP09739981.0A EP2296633B1 (en) | 2008-05-02 | 2009-05-01 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151357T1 true HRP20151357T1 (hr) | 2016-01-29 |
Family
ID=40809930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151357TT HRP20151357T1 (hr) | 2008-05-02 | 2015-12-09 | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10039718B2 (hr) |
| EP (2) | EP3006032A1 (hr) |
| JP (2) | JP5722213B2 (hr) |
| KR (2) | KR101784647B1 (hr) |
| CN (3) | CN102123700A (hr) |
| AP (1) | AP3089A (hr) |
| AU (3) | AU2009242451C1 (hr) |
| BR (1) | BRPI0911871A8 (hr) |
| CA (1) | CA2720856C (hr) |
| CO (1) | CO6321225A2 (hr) |
| CY (1) | CY1117067T1 (hr) |
| DK (1) | DK2296633T3 (hr) |
| EA (2) | EA201591353A1 (hr) |
| EC (1) | ECSP10010636A (hr) |
| ES (1) | ES2553897T3 (hr) |
| HK (2) | HK1153670A1 (hr) |
| HR (1) | HRP20151357T1 (hr) |
| HU (1) | HUE026380T2 (hr) |
| IL (2) | IL208614A (hr) |
| MX (2) | MX2010011963A (hr) |
| NZ (1) | NZ588978A (hr) |
| PL (1) | PL2296633T3 (hr) |
| PT (1) | PT2296633E (hr) |
| SG (2) | SG190618A1 (hr) |
| SI (1) | SI2296633T1 (hr) |
| WO (1) | WO2009135179A2 (hr) |
| ZA (1) | ZA201008007B (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2049506B2 (en) | 2006-07-07 | 2024-05-08 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| LT2487166T (lt) * | 2007-02-23 | 2016-11-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
| WO2009006203A1 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| JP5547066B2 (ja) * | 2007-06-29 | 2014-07-09 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用組成物およびその使用 |
| SG190618A1 (en) | 2008-05-02 | 2013-06-28 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| UA108738C2 (uk) | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
| ME01980B (me) | 2010-11-19 | 2015-05-20 | Gilead Sciences Inc | Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat |
| EP2705027B1 (en) | 2011-05-02 | 2015-06-03 | Gilead Sciences, Inc. | Amorphous solid salts of Cobicistat (GS-9350) |
| ES2651212T3 (es) * | 2011-07-07 | 2018-01-25 | Janssen Sciences Ireland Uc | Formulaciones combinadas de darunavir |
| US8754065B2 (en) | 2011-08-16 | 2014-06-17 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
| WO2013106732A1 (en) | 2012-01-12 | 2013-07-18 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
| KR20140128392A (ko) | 2012-02-03 | 2014-11-05 | 길리애드 사이언시즈, 인코포레이티드 | 제약 작용제를 제조하기 위한 방법 및 중간체 |
| EP2819644A1 (en) | 2012-03-01 | 2015-01-07 | Gilead Sciences, Inc. | Spray dried formulations |
| JP2015534973A (ja) | 2012-10-23 | 2015-12-07 | シプラ・リミテッド | 抗レトロウイルス医薬組成物 |
| WO2014105777A1 (en) | 2012-12-26 | 2014-07-03 | Assia Chemical Industries Ltd. | Cobicostat dichlohydrate salt |
| DE102013205347A1 (de) * | 2013-03-26 | 2014-10-02 | Hilti Aktiengesellschaft | Additiv-Zusammensetzung für Amin-Härter, deren Verwendung sowie diese enthaltende Amin-Härterzusammensetzung |
| CN103230403A (zh) * | 2013-04-23 | 2013-08-07 | 苏州谷力生物科技有限公司 | 一种抗艾滋病毒的组合型药物片剂 |
| AU2014356067A1 (en) | 2013-11-29 | 2016-06-16 | Mylan Laboratories Ltd. | Amorphous cobicistat solid dispersion |
| WO2015145324A1 (en) * | 2014-03-25 | 2015-10-01 | Mylan Laboratories Ltd | Process for the preparation of cobicistat |
| US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| US10166185B2 (en) * | 2015-06-09 | 2019-01-01 | J. Rettenmaier & Söhne Gmbh + Co Kg | Excipient and oral solid dosage forms for oily drugs |
| WO2016201119A1 (en) * | 2015-06-09 | 2016-12-15 | J. Rettenmaier & Söhne Gmbh + Co Kg | Excipient and oral solid dosage forms for oily drugs |
| TW201728582A (zh) | 2016-01-28 | 2017-08-16 | 基利科學股份有限公司 | 結晶型 |
| US20190175511A1 (en) | 2016-08-08 | 2019-06-13 | Hetero Labs Limited | A Multi-Class Anti-Retroviral Composition |
| WO2018029561A1 (en) | 2016-08-08 | 2018-02-15 | Hetero Labs Limited | Anti-retroviral compositions |
| WO2020122242A1 (ja) * | 2018-12-14 | 2020-06-18 | 富士フイルム株式会社 | 医薬組成物及びその製造方法 |
| CN110251476B (zh) * | 2019-08-01 | 2022-08-09 | 海思科制药(眉山)有限公司 | 一种恩曲他滨替诺福韦药物组合物 |
| CN113425702B (zh) * | 2021-06-25 | 2022-08-26 | 中国药科大学 | 应用微流控技术制备纳米颗粒、制备方法及装置和用途 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3400197A (en) | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
| GB1241024A (en) | 1968-10-29 | 1971-07-28 | Boehringer Sohn Ingelheim | Pharmaceutical tablet base and a process for its manufacture |
| FR2096292A5 (hr) | 1970-06-15 | 1972-02-11 | Sumitomo Chemical Co | |
| CH586568A5 (hr) | 1972-04-10 | 1977-04-15 | Hoffmann La Roche | |
| DE2845326C2 (de) | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
| US4603143A (en) | 1983-05-02 | 1986-07-29 | Basf Corporation | Free-flowing, high density, fat soluble vitamin powders with improved stability |
| GB8413191D0 (en) | 1984-05-23 | 1984-06-27 | Beecham Group Plc | Pharmaceutical composition |
| FR2609958B1 (fr) | 1987-01-27 | 1995-03-10 | Honda Motor Co Ltd | Dispositif de support pour roues arriere de motocyclettes |
| FR2631620B1 (fr) | 1988-05-19 | 1990-07-27 | Rhone Poulenc Chimie | Nouvelle silice precipitee absorbante et composition a base de cette s ilice |
| US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5552558A (en) | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| IE20010533A1 (en) | 1990-11-20 | 2003-03-05 | Abbott Lab | Intermediates for preparing retroviral protease inhibiting compounds |
| GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| ZA923641B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| DK0727419T3 (da) | 1992-12-29 | 2002-06-10 | Abbott Lab | Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| WO1995005808A1 (en) | 1993-08-24 | 1995-03-02 | Abbott Laboratories | Oil-based tableting method |
| US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| US5948438A (en) | 1995-01-09 | 1999-09-07 | Edward Mendell Co., Inc. | Pharmaceutical formulations having improved disintegration and/or absorptivity |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| JP4064476B2 (ja) | 1996-03-29 | 2008-03-19 | エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド | 二酸化珪素を有する球状凝集した澱粉 |
| US6348216B1 (en) | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
| US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
| JP4494539B2 (ja) | 1997-02-28 | 2010-06-30 | ディーエスエム アイピー アセッツ ビー．ブイ． | 流動自由な乾燥粒子 |
| FR2767071B1 (fr) | 1997-08-06 | 1999-09-10 | Rhodia Chimie Sa | Composition comprenant un liquide absorbe sur un support a base de silice precipitee |
| JP4027535B2 (ja) | 1998-05-26 | 2007-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 脂溶性薬物を含有した粉末 |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| US20030035834A1 (en) | 2000-05-26 | 2003-02-20 | Pawan Seth | Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release |
| TWI290053B (en) | 2000-09-19 | 2007-11-21 | Daiichi Seiyaku Co | Medicinal composition for preventing the generation of a disagreeable taste |
| US7056951B2 (en) | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
| US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| DE10112651A1 (de) | 2001-03-16 | 2002-09-19 | Degussa | Inhomogene Kieselsäuren als Trägermaterial |
| OA12596A (en) | 2001-05-01 | 2006-06-08 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceuticalcomposition. |
| ES2257559T3 (es) | 2001-05-18 | 2006-08-01 | Lonza Ag | Procedimiento para la preparacion de formulaciones solidas de 3-hidroxi-3-metilbutirato de sodio. |
| DE10126163A1 (de) | 2001-05-30 | 2002-12-05 | Degussa | Pharmazeutische Zubereitungen |
| AU2002325192B2 (en) | 2001-07-06 | 2008-05-22 | Veloxis Pharmaceuticals, Inc. | Controlled agglomeration |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| US7815936B2 (en) | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| DE10153078A1 (de) * | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
| WO2003047551A1 (en) | 2001-11-29 | 2003-06-12 | Penwest Pharmaceutical Company | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| US20030206978A1 (en) | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| US6926906B2 (en) | 2002-02-20 | 2005-08-09 | M./S. Strides, Inc. | Orally administrable pharmaceutical formulation |
| PA8576201A1 (es) | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
| DE10250711A1 (de) | 2002-10-31 | 2004-05-19 | Degussa Ag | Pharmazeutische und kosmetische Zubereitungen |
| CA2470365C (en) | 2002-11-20 | 2011-05-17 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| JP3567162B1 (ja) | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| US7189416B2 (en) | 2002-11-23 | 2007-03-13 | Glykon Technologies Group, Llc | Method for stable and controlled delivery of (-)-hydroxycitric acid |
| ATE398455T1 (de) | 2003-01-14 | 2008-07-15 | Gilead Sciences Inc | Zusammensetzungen und verfahren zur antiviralen kombinationstherapie |
| EP1596835A1 (en) | 2003-02-19 | 2005-11-23 | H. Lundbeck A/S | Method for preparation of an agglomerate using melt agglomeration |
| EP1601347A1 (en) | 2003-02-19 | 2005-12-07 | LifeCycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
| FR2851918B1 (fr) | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
| JP4018664B2 (ja) | 2003-04-30 | 2007-12-05 | 第一三共株式会社 | 安定化固形製剤 |
| DE10337198A1 (de) | 2003-08-13 | 2005-03-17 | Degussa Ag | Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| JP2005075826A (ja) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Internatl Gmbh | 多孔質シリカ担体を含有する徐放性製剤 |
| US20070122482A1 (en) | 2003-10-03 | 2007-05-31 | Per Holm | Method for preparing modified release pharmaceutical compositions |
| JP5069001B2 (ja) | 2003-10-10 | 2012-11-07 | ベロクシス ファーマシューティカルズ エー／エス | フィブラートを含む固体投与形態 |
| US20050096390A1 (en) | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and pravastatin |
| US20060068015A1 (en) | 2003-10-10 | 2006-03-30 | Per Holm | Solid dosage form comprising a fibrate and a statin |
| US20070014846A1 (en) | 2003-10-10 | 2007-01-18 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising fenofibrate and atorvastatin |
| US20050096391A1 (en) | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and rosuvastatin |
| US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
| US20050095287A1 (en) | 2003-10-29 | 2005-05-05 | Matharu Amol S. | Fosinopril composition |
| WO2005084670A1 (en) | 2004-03-01 | 2005-09-15 | Lek Pharmaceuticals D.D. | Pharmaceutical formulation |
| MY142989A (en) | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
| US20050238675A1 (en) | 2004-04-26 | 2005-10-27 | Wenjie Li | Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| WO2006000229A2 (en) | 2004-06-28 | 2006-01-05 | Lifecycle Pharma A/S | Porous tablets as carriers for liquid formulations |
| US20060009603A1 (en) * | 2004-07-09 | 2006-01-12 | David Young | Fibrillation-resistant polypropylene tape |
| AR045841A1 (es) * | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| US20070014854A1 (en) | 2005-07-15 | 2007-01-18 | Ilan Zalit | Novel granulation process |
| JP2007039338A (ja) | 2005-07-29 | 2007-02-15 | Hirofumi Takeuchi | シリカ系複合顆粒 |
| SI2051703T1 (sl) | 2005-12-14 | 2011-01-31 | Cipla Ltd | Farmacevtski sestavki, ki vsebujejo inhibitorje nukleotidne in nukleozidne reverzne transkriptaze (kot tenofovir in lamivudin) v različnih delih dozirne oblike |
| BRPI0620578A2 (pt) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
| BRPI0706280A2 (pt) | 2006-01-05 | 2011-03-22 | Lifecycle Pharma As | produto de comprimido carregável desintegrante, e, método para a preparação de um comprimido carregável desintegrante |
| EP1990062A1 (en) | 2006-02-20 | 2008-11-12 | ASAHI BREWERIES, Ltd. | Granules, tablets and method of producing the same |
| US20070287664A1 (en) | 2006-03-23 | 2007-12-13 | Schering Corporation | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto |
| EP2049506B2 (en) | 2006-07-07 | 2024-05-08 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| UY30535A1 (es) | 2006-08-10 | 2008-03-31 | Cipla Ltd | Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones. |
| EP2063862A2 (en) * | 2006-09-04 | 2009-06-03 | Matrix Laboratories Ltd | Pharmaceutical formulation for use in hiv therapy |
| US7749537B2 (en) | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
| LT2487166T (lt) | 2007-02-23 | 2016-11-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
| WO2009006203A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| JP5547066B2 (ja) | 2007-06-29 | 2014-07-09 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用組成物およびその使用 |
| WO2009037449A1 (en) | 2007-09-18 | 2009-03-26 | Cipla Limited | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| SG190618A1 (en) | 2008-05-02 | 2013-06-28 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| SG10201706215UA (en) * | 2009-02-06 | 2017-08-30 | Gilead Sciences Inc | Tablets for combination therapy |
| EP2238979A1 (en) | 2009-04-06 | 2010-10-13 | LEK Pharmaceuticals d.d. | Active pharmaceutical ingredient adsorbed on solid support |
| TW201728582A (zh) | 2016-01-28 | 2017-08-16 | 基利科學股份有限公司 | 結晶型 |
-
2009
- 2009-05-01 SG SG2013033329A patent/SG190618A1/en unknown
- 2009-05-01 US US12/434,513 patent/US10039718B2/en active Active
- 2009-05-01 JP JP2011507697A patent/JP5722213B2/ja active Active
- 2009-05-01 SI SI200931286T patent/SI2296633T1/sl unknown
- 2009-05-01 DK DK09739981.0T patent/DK2296633T3/en active
- 2009-05-01 MX MX2010011963A patent/MX2010011963A/es active IP Right Grant
- 2009-05-01 CN CN200980115840XA patent/CN102123700A/zh active Pending
- 2009-05-01 ES ES09739981.0T patent/ES2553897T3/es active Active
- 2009-05-01 EA EA201591353A patent/EA201591353A1/ru unknown
- 2009-05-01 CN CN201310447258.1A patent/CN103479584A/zh active Pending
- 2009-05-01 EP EP15184628.4A patent/EP3006032A1/en not_active Withdrawn
- 2009-05-01 HU HUE09739981A patent/HUE026380T2/en unknown
- 2009-05-01 KR KR1020167025826A patent/KR101784647B1/ko active IP Right Grant
- 2009-05-01 PT PT97399810T patent/PT2296633E/pt unknown
- 2009-05-01 NZ NZ588978A patent/NZ588978A/xx unknown
- 2009-05-01 MX MX2014015438A patent/MX342377B/es unknown
- 2009-05-01 KR KR1020107026980A patent/KR101659971B1/ko active IP Right Grant
- 2009-05-01 AP AP2010005429A patent/AP3089A/xx active
- 2009-05-01 CN CN201510408376.0A patent/CN104940937A/zh active Pending
- 2009-05-01 CA CA2720856A patent/CA2720856C/en active Active
- 2009-05-01 AU AU2009242451A patent/AU2009242451C1/en active Active
- 2009-05-01 EA EA201071173A patent/EA022950B1/ru unknown
- 2009-05-01 PL PL09739981T patent/PL2296633T3/pl unknown
- 2009-05-01 BR BRPI0911871A patent/BRPI0911871A8/pt not_active IP Right Cessation
- 2009-05-01 EP EP09739981.0A patent/EP2296633B1/en not_active Revoked
- 2009-05-01 WO PCT/US2009/042607 patent/WO2009135179A2/en active Application Filing
- 2009-05-01 SG SG10201609006WA patent/SG10201609006WA/en unknown
-
2010
- 2010-10-11 IL IL208614A patent/IL208614A/en active IP Right Review Request
- 2010-10-28 CO CO10134187A patent/CO6321225A2/es not_active Application Discontinuation
- 2010-11-09 ZA ZA2010/08007A patent/ZA201008007B/en unknown
- 2010-11-26 EC EC2010010636A patent/ECSP10010636A/es unknown
-
2011
- 2011-08-02 HK HK11107966.2A patent/HK1153670A1/zh unknown
-
2013
- 2013-10-22 JP JP2013218876A patent/JP5925171B2/ja active Active
-
2014
- 2014-09-03 AU AU2014221210A patent/AU2014221210C1/en active Active
-
2015
- 2015-12-09 HR HRP20151357TT patent/HRP20151357T1/hr unknown
- 2015-12-22 CY CY20151101168T patent/CY1117067T1/el unknown
-
2016
- 2016-03-30 HK HK16103674.9A patent/HK1215679A1/zh unknown
- 2016-08-22 IL IL247417A patent/IL247417A0/en unknown
- 2016-10-28 AU AU2016250470A patent/AU2016250470A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151357T1 (hr) | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa | |
| JP2021075566A5 (hr) | ||
| ES2548886T3 (es) | Comprimidos bicapa que comprenden elvitegravir, cobicistat, emtricitabina y tenofovir | |
| TWI417098B (zh) | （阿伐ｓ，貝他ｒ）-６-溴-阿伐-〔２-（二甲胺基）乙基〕-２-甲氧基-阿伐-１-萘-貝他-苯基-３-喹啉乙醇 | |
| JP2013545752A5 (hr) | ||
| WO2014093941A1 (en) | Pharmaceutical compositions | |
| TWI480067B (zh) | 經包衣之固體製劑 | |
| Cao et al. | Oral bioavailability of silymarin formulated as a novel 3-day delivery system based on porous silica nanoparticles | |
| CA2778748A1 (en) | Particulate preparation and method for producing the same | |
| SI2760821T1 (en) | A salt salt of an anti-inflammatory substituted cyclobutenedione compound | |
| CA2585859A1 (en) | Particles for treatment of pulmonary infection | |
| KR101406859B1 (ko) | 고형 제제용의 필름 코팅제 및 이것을 사용한 고형 제제 | |
| JP2011507896A5 (hr) | ||
| CA2961528A1 (en) | Long acting pharmaceutical compositions | |
| CA2789443A1 (en) | Nucleoside phosphonate salts | |
| JP2013505233A5 (hr) | ||
| IL269296B2 (en) | A pharmaceutical preparation that includes high amounts of medium chain triglycerides and a related method | |
| JP2007509891A5 (hr) | ||
| KR20170141774A (ko) | 항바이러스 및 항염증 치료제의 치료 조합물 | |
| KR101918211B1 (ko) | 트리메타지딘의 장기간 방출을 위한 약제학적 조성물 | |
| CN101190912A (zh) | 新的抗病毒化合物及其制备方法 | |
| JP2019532939A5 (hr) | ||
| WO2013151518A1 (en) | Capsule formulations comprising ceftibuten | |
| HRP20150410T1 (hr) | Novi pripravci za terapiju esencijalne trombocitemije | |
| JP2013014568A (ja) | 単純ヘルペスウイルスを処置するための組成物および方法 |